Fig. 3: Subgroup analyses of PFS (FAS). | Nature Medicine

Fig. 3: Subgroup analyses of PFS (FAS).

From: Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Fig. 3

HRs (center square) with 95% CIs (error bars) for PFS in the atezo-chemo group versus the placebo-chemo group in the FAS. HRs with CIs were calculated using the Cox proportional hazards method. The number of patients in each subgroup/arm is indicated. Intrinsic subtype, PD-L1 status, TIS, tumor lymphocyte infiltration and TMB were not available for all patients.

Back to article page